[{"id":"8928481a-724a-435c-8656-726fa0e4aab3","acronym":"GLYCAR","url":"https://clinicaltrials.gov/study/NCT02905188","created_at":"2021-03-12T22:55:55.778Z","updated_at":"2025-02-25T12:26:31.981Z","phase":"Phase 1","brief_title":"Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)","source_id_and_acronym":"NCT02905188 - GLYCAR","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GLYCAR T cells • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 03/28/2019","start_date":" 03/28/2019","primary_txt":" Primary completion: 11/17/2021","primary_completion_date":" 11/17/2021","study_txt":" Completion: 01/06/2023","study_completion_date":" 01/06/2023","last_update_posted":"2025-02-24"},{"id":"8009476b-712f-4b6f-9467-7f222bfb4fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05450562","created_at":"2022-07-08T14:55:40.019Z","updated_at":"2024-07-02T16:35:00.176Z","phase":"Phase 1/2","brief_title":"Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05450562","lead_sponsor":"Sanofi","biomarkers":" ALK • GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["ALK • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • SAR444200"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 12/12/2030","primary_completion_date":" 12/12/2030","study_txt":" Completion: 12/12/2030","study_completion_date":" 12/12/2030","last_update_posted":"2024-05-30"},{"id":"fc576648-b27b-43b1-9571-31217d6f4b7e","acronym":"ATHENA","url":"https://clinicaltrials.gov/study/NCT06084884","created_at":"2023-10-16T15:12:58.306Z","updated_at":"2024-07-02T16:35:02.183Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","source_id_and_acronym":"NCT06084884 - ATHENA","lead_sponsor":"AstraZeneca","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 12/13/2027","primary_completion_date":" 12/13/2027","study_txt":" Completion: 12/13/2027","study_completion_date":" 12/13/2027","last_update_posted":"2024-05-21"},{"id":"2ffdf6d6-d9b4-4d82-87df-b8731e5b67ba","acronym":"ARYA3","url":"https://clinicaltrials.gov/study/NCT04864054","created_at":"2021-04-28T12:52:53.604Z","updated_at":"2024-07-02T16:35:05.862Z","phase":"Phase 2","brief_title":"T-Cell Therapy (ECT204) in Adults With Advanced HCC","source_id_and_acronym":"NCT04864054 - ARYA3","lead_sponsor":"Eureka Therapeutics Inc.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Stivarga (regorafenib) • ECT204"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-06"},{"id":"a50db79e-f985-4b65-9c1b-fc575cc8904a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04715191","created_at":"2021-01-21T06:52:06.961Z","updated_at":"2024-07-02T16:35:05.923Z","phase":"Phase 1","brief_title":"Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors","source_id_and_acronym":"NCT04715191","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GLYCAR T cells • GPC3-CAR and IL15 plus IL21 • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/03/2024","start_date":" 07/03/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 07/03/2041","study_completion_date":" 07/03/2041","last_update_posted":"2024-05-06"},{"id":"a01a09c6-25d1-401d-bdb6-9d279e055486","acronym":"","url":"https://clinicaltrials.gov/study/NCT05070156","created_at":"2021-10-07T12:53:00.198Z","updated_at":"2024-07-02T16:35:26.134Z","phase":"Phase 1","brief_title":"B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT05070156","lead_sponsor":"Tongji University","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e B010-A"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2023-12-15"},{"id":"f006991a-381f-4af1-aee4-1aabbfd0f738","acronym":"","url":"https://clinicaltrials.gov/study/NCT06088459","created_at":"2023-10-18T16:14:28.892Z","updated_at":"2024-07-02T16:35:32.927Z","phase":"Phase 1","brief_title":"NWRD06 DNA Plasmid for HCC After Radical Resection","source_id_and_acronym":"NCT06088459","lead_sponsor":"Newish Technology (Beijing) Co., Ltd.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-18"},{"id":"ee94b79f-8da0-407f-bc94-ca8110bf7bd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05103631","created_at":"2021-11-02T17:57:08.812Z","updated_at":"2024-07-02T16:35:39.256Z","phase":"Phase 1","brief_title":"Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors","source_id_and_acronym":"NCT05103631","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AGAR T cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/17/2021","start_date":" 06/17/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 12/01/2039","study_completion_date":" 12/01/2039","last_update_posted":"2023-08-23"},{"id":"f621ba59-cb59-4206-a05e-20a12949ff48","acronym":"","url":"https://clinicaltrials.gov/study/NCT04377932","created_at":"2021-01-19T19:44:24.215Z","updated_at":"2024-07-02T16:35:43.615Z","phase":"Phase 1","brief_title":"Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors","source_id_and_acronym":"NCT04377932","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AGAR T cells • GLYCAR T cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2040","study_completion_date":" 02/01/2040","last_update_posted":"2023-07-07"},{"id":"fb860809-ebea-4c05-af96-bfe14c08cdf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02932956","created_at":"2021-03-12T11:53:07.388Z","updated_at":"2024-07-02T16:35:46.433Z","phase":"Phase 1","brief_title":"Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)","source_id_and_acronym":"NCT02932956","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GAP T cells • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/17/2018","start_date":" 12/17/2018","primary_txt":" Primary completion: 09/27/2021","primary_completion_date":" 09/27/2021","study_txt":" Completion: 02/01/2037","study_completion_date":" 02/01/2037","last_update_posted":"2023-06-06"},{"id":"76788d04-ecba-4ab1-ae56-720959e57ded","acronym":"ZZCART-003","url":"https://clinicaltrials.gov/study/NCT03198546","created_at":"2021-03-26T09:09:10.078Z","updated_at":"2024-07-02T16:35:54.565Z","phase":"Phase 1","brief_title":"GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression","source_id_and_acronym":"NCT03198546 - ZZCART-003","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TGFβ targeting CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2023-02-28"},{"id":"38d28b1c-b832-4135-9431-71952b7272aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05620706","created_at":"2022-11-17T14:57:08.278Z","updated_at":"2024-07-02T16:36:00.046Z","phase":"","brief_title":"Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma","source_id_and_acronym":"NCT05620706","lead_sponsor":"Shenzhen University General Hospital","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2022-11-22"},{"id":"28d0bd62-5b35-49f3-a30f-5616172cf246","acronym":"","url":"https://clinicaltrials.gov/study/NCT05263960","created_at":"2022-03-03T14:06:10.705Z","updated_at":"2024-07-02T16:36:09.149Z","phase":"Phase 1/2","brief_title":"A Study of CM350 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05263960","lead_sponsor":"Keymed Biosciences Co.Ltd","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CM350 • Kangyueda (stapokibart)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 04/21/2022","start_date":" 04/21/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2022-06-09"},{"id":"a9305ff1-8168-48d4-a6d2-1d32391a5c57","acronym":"","url":"https://clinicaltrials.gov/study/NCT05344664","created_at":"2022-04-25T21:58:10.116Z","updated_at":"2024-07-02T16:36:11.522Z","phase":"Phase 1","brief_title":"Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma","source_id_and_acronym":"NCT05344664","lead_sponsor":"Peking University","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3-CAR-T cells"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 10/14/2024","primary_completion_date":" 10/14/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2022-04-25"},{"id":"1f1d6176-deb9-471d-b25a-15537effeb32","acronym":"","url":"https://clinicaltrials.gov/study/NCT04506983","created_at":"2021-01-19T20:11:24.824Z","updated_at":"2024-07-02T16:36:17.199Z","phase":"Phase 1","brief_title":"GPC3-CAR-T Cells for the Hepatocellular Carcinoma","source_id_and_acronym":"NCT04506983","lead_sponsor":"Beijing Tsinghua Chang Gung Hospital","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3-CAR-T Cells"],"overall_status":"Suspended","enrollment":" Enrollment 12","initiation":"Initiation: 06/10/2022","start_date":" 06/10/2022","primary_txt":" Primary completion: 06/10/2023","primary_completion_date":" 06/10/2023","study_txt":" Completion: 10/10/2023","study_completion_date":" 10/10/2023","last_update_posted":"2022-02-14"},{"id":"08310589-48de-424e-82b3-d1923ffca137","acronym":"","url":"https://clinicaltrials.gov/study/NCT03302403","created_at":"2021-01-18T16:18:51.239Z","updated_at":"2024-07-02T16:36:40.277Z","phase":"","brief_title":"Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors","source_id_and_acronym":"NCT03302403","lead_sponsor":"Kang YU","biomarkers":" CLDN18 • GPC3","pipe":" | ","alterations":" CD19 positive • GPC3 positive","tags":["CLDN18 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • satricabtagene autoleucel (CT041) • CT011 • CT0180 • CT032 • cyclophosphamide intravenous • zevorcabtagene autoleucel (CT053)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/29/2017","start_date":" 12/29/2017","primary_txt":" Primary completion: 12/12/2020","primary_completion_date":" 12/12/2020","study_txt":" Completion: 12/12/2023","study_completion_date":" 12/12/2023","last_update_posted":"2020-10-08"},{"id":"f8fffc52-71a3-426b-a634-3f9362743182","acronym":"","url":"https://clinicaltrials.gov/study/NCT04093648","created_at":"2021-01-19T18:37:56.679Z","updated_at":"2024-07-02T16:36:44.889Z","phase":"Phase 1","brief_title":"T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)","source_id_and_acronym":"NCT04093648","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GLYCAR T cells • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 01/01/2038","study_completion_date":" 01/01/2038","last_update_posted":"2020-05-20"},{"id":"bb14f754-057f-42b3-a78b-090a95232262","acronym":"","url":"https://clinicaltrials.gov/study/NCT03146234","created_at":"2021-01-19T14:08:15.002Z","updated_at":"2024-07-02T16:36:56.215Z","phase":"","brief_title":"CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma","source_id_and_acronym":"NCT03146234","lead_sponsor":"RenJi Hospital","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CT0180"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 10/18/2018","primary_completion_date":" 10/18/2018","study_txt":" Completion: 10/18/2018","study_completion_date":" 10/18/2018","last_update_posted":"2019-08-28"},{"id":"e8843255-9af2-4b2f-8788-b94f4751a0d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02395250","created_at":"2021-01-19T10:04:57.412Z","updated_at":"2024-07-02T16:36:56.191Z","phase":"Phase 1","brief_title":"Anti-GPC3 CAR T for Treating Patients With Advanced HCC","source_id_and_acronym":"NCT02395250","lead_sponsor":"RenJi Hospital","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2019-08-28"},{"id":"5506a039-637a-4f14-9feb-30df14fa6ca9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02748837","created_at":"2021-03-26T08:15:12.358Z","updated_at":"2024-07-02T16:36:56.662Z","phase":"Phase 1","brief_title":"A Study of ERY974 in Patient With Advanced Solid Tumors","source_id_and_acronym":"NCT02748837","lead_sponsor":"Chugai Pharmaceutical","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERY974"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 08/01/2019","primary_completion_date":" 08/01/2019","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2019-08-22"},{"id":"b44b4a42-418f-4b9c-993b-2405ea6f63e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03084380","created_at":"2021-03-26T08:54:47.798Z","updated_at":"2024-07-02T16:37:24.309Z","phase":"Phase 1/2","brief_title":"Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT03084380","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 05/31/2019","primary_completion_date":" 05/31/2019","study_txt":" Completion: 05/31/2020","study_completion_date":" 05/31/2020","last_update_posted":"2017-03-20"},{"id":"a4e18afb-a3de-4870-9081-352daa6c3503","acronym":"","url":"https://clinicaltrials.gov/study/NCT02876978","created_at":"2021-03-26T08:29:47.315Z","updated_at":"2024-07-02T16:37:29.595Z","phase":"Phase 1","brief_title":"Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT02876978","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CT0180 • cyclophosphamide intravenous"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 04/01/2019","study_completion_date":" 04/01/2019","last_update_posted":"2016-08-24"}]